This clinical observation describes the enteral nutrition (EN) management of 2 toddlers at high nutrition risk due to cystic fibrosis (CF), exocrine pancreatic insufficiency, and comorbid medical conditions. The first case report describes a boy with severe malabsorption after intestinal resection. The second case report reviews a boy with CF and neuroblastoma. When pancreatic enzyme replacement therapy with EN was not effective or appropriate, use of an in-line digestive cartridge was initiated. While using the digestive cartridge, both children showed improvements in their anthropometric measures. This observation reviews the nutrition management throughout their clinical course and describes the use of a digestive cartridge with EN. (Nutr Clin Pract. 2018;33:286-294) 
Introduction
Cystic fibrosis (CF) is an autosomal recessive disease affecting approximately 30,000 children and adults in the United States, with 64% of CF diagnoses now being made at birth through universal newborn screening.
1,2 CF results from mutations to the gene that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. 1 CFTR is an ion channel that regulates the flow of chloride and bicarbonate in and out of epithelial cells. Malfunction of the CFTR protein disrupts the cellular transport of ions and water, resulting in viscous secretions in the lungs, pancreas, gastrointestinal (GI) tract, and other organs, impairing the overall functionality of the affected organ. 1 One of the principles of CF care emphasized to parents immediately after diagnosis is the importance of nutrition. It has been well documented that poor nutrition contributes to unfavorable outcomes over time for children and adults with CF. [3] [4] [5] [6] [7] Special attention is placed on the nutrition status of infants and toddlers, who are at an especially vulnerable stage of growth and development. For children with chronic disease, growth failure at younger than 2 years of age can lead to short stature, which may not be overcome with added calories for catch-up growth. 8 Evidence-based practice guidelines recommend that children with CF maintain adequate weight gain and growth to preserve long-term pulmonary function and survival. 3 Formal recommendations from the CF Foundation call for children to attain a weight-for-length status at or above the 50th percentile by age 2. 4 Children and adults with CF are at high risk of malnutrition due to increased baseline energy expenditure, poor oral intake, and nutrient malabsorption from exocrine pancreatic insufficiency (EPI). Comorbidities such as CFrelated liver disease and CF-related diabetes can also contribute to poor nutrition status. 1, 4 The most severe classes of CFTR gene mutations cause damage to the pancreas in utero, leading to 85% of CF infants being pancreatic insufficient at birth. 1, 9 Among those who are pancreatic sufficient, 25% may develop pancreatic insufficiency by age 3, whereas others can develop EPI in adulthood. 1, 10 GibsonCorley and colleagues 9 described the pathophysiology of pancreatic disease in CF. Thickened secretions obstruct acinar cells and pancreatic ducts, blocking the flow of digestive enzymes and bicarbonate from the pancreas to the duodenum. As the disease progresses, this causes inflammation and fibrosis of pancreatic tissue. 9 The absence of pancreatic enzymes and bicarbonate results in maldigestion of macronutrients, malabsorption of fat-soluble vitamins, and micronutrient losses in stool. 1 Malabsorbed macronutrients, especially fat, can cause unpleasant GI symptoms such as bloating, abdominal cramping, flatulence, and steatorrhea.
To achieve adequate growth and weight gain, children with CF may require 110%-200% of the calorie needs of healthy children in the same age range, with 30%-40% of these calories coming from fats. 3, 5, 11 When children and adults with CF are unable to maintain an adequate nutrition status with a high-calorie oral diet, enteral nutrition (EN) may be recommended. Supplemental EN is considered a proactive therapeutic option to promote growth and improve outcomes in those struggling to maintain weight and is presented to families as a standard of care for CF management. 5 According to the 2015 Patient Registry Annual Data Report from the Cystic Fibrosis Foundation, approximately 11.7% of people with CF use supplemental EN, a value that has been gradually increasing since 2000. 12 Oral pancreatic enzyme replacement therapy (PERT), also known as pancrelipase, is the standard treatment for EPI. It is initiated based on the patient's genotype, the results of direct or indirect measurement of pancreatic function, or clinical symptoms such as steatorrhea. 1, 5 The fecal elastase test is a common indirect test used to detect pancreatic insufficiency. The fecal eslastase test is preferred because it requires only a small stool sample and can be used while patients are actively taking pancrelipase medication. 1 Pancreatic enzymes are available in the form of capsules or tablets and vary in dose and size. [13] [14] [15] [16] [17] Encapsulated pancrelipase products contain enteric-coated enzyme microspheres designed to dissolve in the small intestine and begin nutrient digestion. [13] [14] [15] 17 These microspheres require a pH of 5.5-6.0 to be effective. 1, 18 In CF, a lack of bicarbonate release from the pancreas may prevent adequate neutralization of pH in the duodenum. As a result, enzyme microspheres may not dissolve until they reach distal portions of the GI tract, leaving some macronutrients undigested or causing them to miss crucial absorptive surfaces. 1, 18 Although dosing strategies may vary among CF clinicians, general guidelines are followed when prescribing oral enzymes. The strength of pancrelipase medication is based on the units of lipase provided by the capsule or tablet. It can be prescribed based on body weight or grams of fat in food or formula. 1, 4 When providing pancrelipase based on grams of ingested fat, recommendations can range from 500-4000 units of lipase per gram of fat. 1, 4 The recommended upper limit of PERT dosing is 2500 units of lipase per kilogram body weight per meal, and 10,000 units of lipase per kilogram body weight per day. 1, 3 In addition, medication to suppress or neutralize gastric acid secretion may be prescribed in an attempt to optimize enzyme therapy. 1 Although dosing guidelines are well established for the use of pancreatic enzymes with oral meals and snacks, there are no evidence-based recommendations for the use of PERT with EN. 5, 10, 19 The use of oral enzymes with cyclic or continuous EN therapy has been based on best practice experience in an effort to maximize calorie absorption for people who otherwise cannot digest macronutrients in formula. Different techniques to administer enzymes with EN exist and vary among institutions. [19] [20] [21] However, these techniques are not approved by the Food and Drug Administration (FDA) based on manufacturer labeling and have not been evaluated in a clinical trial. [13] [14] [15] [16] [17] 19 One manufacturer recently updated the package insert, outlining directions for administering pancrelipase microspheres through a gastrostomy tube (GT). 17 However, evidence is not available to support the clinical efficacy of this method.
To fulfill the unmet need for fats hydrolysis with continuous EN, a digestive cartridge called RELiZORB (Alcresta Therapeutics, Inc, Newton, MA) was developed. It became available on the market in 2015. It is a lipase cartridge that has been approved by the FDA for use in adults and children (ages 5 and older) to hydrolyze fats in enteral formula. 22 The device connects in-line with the enteral formula tubing. Inside the cartridge there are acrylic beads with covalently bound lipase enzymes attached, known as the iLipase complex (immobilized lipase). The lipase cartridge allows for the ex vivo hydrolysis of fats, without the presence of colipase or bicarbonate. 22 Similar to pancreatic lipase, the microbialbased lipase specifically cleaves triglyceride molecules at the sn-1 and sn-3 positions. As formula passes through the cartridge, triglycerides in the formula are digested by the lipase enzyme, delivering fats to the GI tract in the form of monoglycerides and free fatty acids. 22 Filters on both ends of the cartridge contain the beads within the device. The patients are not exposed to the enzyme during use.
The cartridge is a disposable, single-use device indicated for 500 mL of formula per unit. It is compatible with pump systems with low flow or no flow alarms at rates between 24 and 120 mL/hr. 22 Based on manufacturer labeling, up to 2 cartridges can be used in a 24-hour period. A multicenter, randomized, double-blind, placebo-controlled, crossover study concluded that use of the digestive cartridge was safe and well tolerated in children and adults. 23 The study also demonstrated use of the cartridge increases plasma levels of the ω-3 fatty acids, eicosapentaenoic acid, and docosahexaenoic acid when administered with a formula fortified with these nutrients. 23 In the clinical cases described herein, the routine medical care of both children with CF was complicated by another complex medical condition. Both children received supplemental EN through a feeding tube to help improve their nutrition status and clinical course. EN was initiated at 4 months old and 21 months old, respectively. In the first case, traditional EN and enzyme protocols were exhausted. Despite aggressive intervention, the child experienced poor weight gain and intolerance of EN until the digestive cartridge was introduced. In the second case, oral pancreatic enzymes were not used with EN due to the complexity of the child's care. The experiences and outcomes of using the digestive cartridge in combination with EN is described in these 2 pediatric clinical observations.
Case Presentations

Case 1
Patient 1 is a 2-year-old boy with CF. He has 1 copy each of the F508del and G542X CFTR gene mutations. He also has malnutrition from EPI, gastroesophageal reflux (GER), and a previous small bowel resection.
Patient 1 was born at 34 weeks' gestation with meconium ileus (MI) and volvulus. At 3 days old, he underwent surgical removal of 15 cm of gangrenous bowel and creation of an ileostomy with mucous fistula. One month later, he was unable to take oral feedings and required insertion of a tunneled central line for parenteral nutrition (PN) and fat infusions. Reversal of the ileostomy and reanastamosis were performed at 2 months of age. He was accepting 40 mL of breast milk via bottle in addition to on-demand breastfeeding, with 21% of calories coming from PN. At that time, the patient weighed 2.84 kg, which was below the second percentile according to the World Health Organization weight-for-age growth chart. By 4 months of age, his weight was still below the second percentile for age, with a slight improvement in z score from −5.67 at 2 months to −4.90 at 4 months.
At 4 months of age, the central line was removed and a GT was placed for EN. He started on a 24 kcal/oz hypoallergenic formula with extensively hydrolyzed protein, with a goal volume of 288 mL overnight in addition to breastfeeding every 2-3 hours on demand during the day (approximately 6 times daily). Breastfeeding provided approximately 360-480 kcal daily in addition to the overnight feedings, which provided 223 kcal. Breastfeeding and overnight feedings provided 143 kcal/kg body weight and 2.5 g/kg protein.
Based on inadequate growth identified during a followup appointment a few weeks later, the overnight formula concentration was increased to 27 kcal/oz.
Given patient 1's EPI, PERT was prescribed with his EN regimen. Initially, a nonenteric coated pancrelipase product was crushed, dissolved in water, and added to the formula prior to infusion. One enzyme tablet provided 20,880 units of lipase with the overnight feeding (1740 units of lipase per gram of fat). This method required at least 30 minutes of preparation time, adding to the overall treatment burden for his parents. Patient 1 also had symptoms of GER and projectile emesis. At 5 months of age, his formula was concentrated further to 30 kcal/oz. The enzyme prescription was increased to 1.5 nonenteric coated tablets, providing 31,320 units of lipase with overnight feeds (1977 units of lipase per gram of fat).
At 9 months of age, patient 1 continued to have very poor weight gain, malnutrition, and severe GER despite antireflux medications, frequent clinic visits, and phone contact with a pulmonologist and nutritionist. He weighed 6.24 kg, which was below the second percentile for age, with a z score of −3.28. He was receiving 432 mL of the extensively hydrolyzed infant formula, concentrated to 30 kcal/oz, overnight for 12 hours. This provided 432 calories and 12 grams of protein (70 kcal/kg, 2.0 g/kg protein), which supplemented his daytime breast milk intake. The enzyme dose with overnight feeds was increased to 2 nonenteric coated crushed tablets (41,760 units of lipase, 1,758 units of lipase per gram of fat). At this time, feeding pump malfunctions occurred, inhibiting delivery of the full volume of formula every night.
Because of ongoing severe GI symptoms, the GT was converted to a gastro-jejunal feeding tube, with continuation of a 30 kcal/oz formula for 12 hours overnight. Next, his enzyme regimen was changed to an enteric-coated enzyme, which needed to be dissolved in 5 mL bicarbonate and given via syringe through the gastrostomy port every 4 hours overnight. At this time, patient 1 was having difficulty taking solid foods due to gagging and oral aversion. Feeding therapy was initiated to optimize oral food intake. His weight gain improved with the placement of the gastrojejunal feeding tube, but his weight remained below the second percentile for age according to the World Health Organization growth charts. In addition to feeding challenges, the new enzyme regimen added to the preparation time for his medication, requiring enzyme administration every 4 hours through the night during enteral feeding.
At 10 months of age, patient 1 weighed 7.08 kg, which was below the second percentile for age, with a z score of −2.56. His length was 71.3 cm, which was at the ninth percentile for age, with a weight-for-length z score of −2.65. These low z scores reflected continued malnutrition despite maximizing calories with EN.
During the next 14 months, patient 1 continued to have poor weight gain and growth. During this time, he was evaluated monthly in a CF clinic, requiring treatment with oral antibiotics for multiple CF-related infections. He required ongoing management of oral aversion, frequent emesis, and intermittent constipation. Despite adequate pancrelipase dosing, patient 1 continued to have malabsorption symptoms. Next, the enzyme regimen with enteral feeding was changed back to crushing and adding nonenteric coated tablets directly to the formula. The gastrojejunal feeding tube became dislodged several times and required replacement in the operating room under general anesthesia. At 23 months of age, patient 1 had a Nissen fundoplication and conversion back to a GT. The family was very adherent to all prescribed treatments and medications. Overnight home nursing also assisted with his treatment regimen. Patient 1 continued with poor tolerance of overnight feeds, gagging, and retching. He also had poor weight gain, loose stools, and significant feeding aversions.
At 24 months of age, enzyme replacement therapy was stopped, and the digestive cartridges were initiated with his overnight EN. Each night, he received 500 mL of a 1.5 kcal/mL peptide-based formula with 1 digestive cartridge. The supplemental formula provided 750 calories and 34 grams of protein (79 kcal/kg, 3.6 g/kg protein). There was a significant improvement in both linear growth and weight after introducing the cartridge. Between 24 and 32 months of age, patient 1 gained 3.62 kg, with an improvement in his weight-for-age percentile from less than the second to the 31st. He grew 6.6 cm in length, with an improvement in his length-for-age percentile from less than the second to the fifth. Prior to introducing the cartridge, patient 1's weight-for-length percentile was never higher than the 15th percentile. By 32 months of age, he reached the 82nd percentile for body mass index (BMI) for age.
After the transition to the digestive cartridge, patient 1 experienced significantly fewer episodes of emesis and loose stools. His tolerance for oral meals also improved slightly, but the variety and portion sizes of foods he accepted were limited. Patient 1 required additional feeding therapy to optimize his oral intake. The parents voiced a preference for the digestive cartridge, recognizing its ease of use when compared with previous enzyme alternatives.
Case 2
Patient 2 is a 2-year-old boy, born at term by cesarean section without complication. His newborn screen was positive for CF, confirmed with a positive sweat test. Genetic testing identified the F508del and R117H/7T gene mutations.
For the first 6 months of life, he had adequate growth as a breastfed baby, tracking at approximately the 15th weightfor-age percentile and 20-40th weight-for-length percentiles according to the Center for Disease Control and Prevention growth charts. He did not show any signs of malabsorption, and a fecal elastase level was not obtained. At 6 months of age, he weighed 6.7 kg and was 64.8 cm long, which were in the eighth and 19th percentiles for age, respectively. He was at the 22nd weight-for-length percentile.
When patient 2 was 7 months old, his oral intake declined because he refused to drink from a bottle after his nursing mother returned to work. He was admitted to the hospital at 8 months of age with a marked 1.3-kg weight loss, hyponatremia, and dehydration. With the 19% loss of body weight, his weight dropped to less than the third percentile for age. The dehydration and hyponatremia resolved with intravenous fluids. While hospitalized, he began to drink bottled expressed breast milk concentrated with standard infant formula to 27 kcal/oz, with a goal of 150 kcal/kg/day. During this hospitalization, the results from a fecal elastase test were low normal, at 241 mcg/g stool (normal >201 mcg/g). Stools had a yellow, seedy appearance, consistent with a breast milk diet. His weight trajectory improved to the sixth weight-for-age percentile and the 41st weight-forlength percentile by the time he was 10 months old.
At approximately 16 months of age, patient 2 had a progressive decrease in oral intake associated with irritability, fatigue, and what appeared to be parotid gland swelling. After an extensive diagnostic evaluation, he was diagnosed as having stage IV neuroblastoma and was treated aggressively with radiation and chemotherapy. At that time, patient 2 weighed 9.7 kg. He was at the eighth weight-forage percentile and the 42nd weight-for-length percentile. His poor oral intake persisted, which resulted in further weight loss to a weight below the fifth percentile for age. His growth improved after receiving PN for 3 months.
At 21 months of age, a GT was placed because of his ongoing refusal to eat and need for long-term supplemental nutrition. He was prescribed a 1.5 kcal/mL peptide-based formula with a goal of 1200 calories and 36 grams of protein per day (118 kcal/kg, 3.5 g/kg protein). Initially, he was prescribed daytime bolus feeds and cyclic overnight feeds. During the same hospital admission, a repeat fecal elastase test confirmed EPI, with a fecal elastase level <15 mcg/g stool. He was started on oral PERT, with approximately 1400 units of lipase per gram of fat with each bolus feed. However, the patient refused to take enzymes by mouth with food or GT feedings. Consideration was given to the popular method of crushing pancreatic enzyme microspheres and dissolving them in sodium bicarbonate before adding the mixture to a feeding bag with formula. However, members of the medical team did not think this regimen was viable at home because of the overall burden of his care.
To reduce his dependence on PN and deliver EN with effective enzyme coverage, the digestive cartridge was initiated with enteral feedings. At this time, patient 2 weighed 11.2 kg, measured 81 cm, and was at the 60th weight-for-length percentile. Patient 2's weight-for-age and length-for-age were at the 21st and 13th percentiles, respectively. Initially, he received 800 mL of a 1.5 kcal/mL peptidebased formula over 16 hours, with 1 cartridge for each 500 mL of formula (a total of 2 cartridges). He continued to refuse all oral daytime feedings. His tolerance of EN was limited by posttussive emesis and chemotherapy side effects. To address tolerance challenges, feedings were maintained on a continuous schedule with a higher rate during the day and a lower rate overnight during sleep. Patient 2 received 500-800 mL of formula per day based on tolerance, with 1-2 cartridges daily depending on total volume. The formula provided approximately 750-1200 calories and 22-36 grams of protein daily (67-107 kcal/kg and 2.0-3.2 g/kg protein). During the next month, patient 2 gained 0.33 kg without using PN. His entire source of nutrition came from enteral feeding through the digestive cartridge. At 22 months of age, he weighed 11.53 kg, measured 82.6 cm long, and was at the 58th weight-for-length percentile. His weight for age reached the 25th percentile and length for age reached the 19th percentile.
Patient 2 has since undergone fully ablative chemotherapy followed by a 2-stage stem cell transplant and is recovering nicely. As his symptoms have improved, he accepts some oral feedings but still refuses enzymes orally. The ongoing goal is 800 mL of a 1.5 kcal/mL peptide-based formula daily with 1 digestive cartridge. This provides 100% of his estimated nutrition needs for growth (104 kcal/kg, 3.2 g/kg protein, and 54 grams of total fat per day).
During his recovery from the 2-stage stem cell transplant, he required some decrease in the enteral feeding rate due to nausea and vomiting. However, he tolerated the digestive cartridge well. Initially, the weight of the cartridge caused irritation at the stoma site. His parents addressed this by anchoring the cartridge to the pole during the daytime feeding and affixing the cartridge to a nightstand during overnight feeding. These strategies effectively prevented the weight of the cartridge from pulling on the GT site.
Since starting GT feeds with the digestive cartridge, patient 2 has gained weight and grown in length. At 24 months of age, he weighed 10.4 kg, measured 82.7 cm in length, and was at the 11th BMI-for-age percentile. At 28 months of age, he weighed 12 kg, was 86 cm long, and reached the 46th BMI-for-age percentile. His progression can be seen on the growth charts in Figures 1 and 2 .
Discussion
CF is a chronic illness with a high treatment burden that puts patients at risk for malnutrition at an early age. When patients with CF have additional medical conditions, complex management may be complicated further by added therapies and nutrition demands. The cases presented in this clinical observation demonstrate many of the challenges faced by pediatric patients with CF and comorbid medical condtions.Together, these case studies identify an urgent need to address complications of EPI and fat malabsorption in children receiving EN. They outline the experiences of children who benefitted from the use of a digestive cartridge with EN and demonstrate the positive effects the device had on their nutrition outcomes and overall care plans.
At the time the patients were being treated, the digestive cartridge was being prescribed for adults with CF using EN. Formal data for use of the cartridge in children were not available. The device also did not have a pediatric indication from the FDA. However, healthcare providers were able to prescribe the device for children at their discretion. In July 2017, the FDA cleared the device for use in children ages 5 and older. For these cases, however, the use of the device is still considered off label based on age.
Despite the lack of clinical evidence at the time of initial prescription, the care teams were comfortable using the cartridge and discontinuing oral enzymes with enteral tube feeding for several reasons. First, both cases involved a highrisk patient with urgent need and limited treatment options. In patient 1's case, several strategies for combining oral enzyme therapy with EN were already exhausted unsuccessfully. A common strategy of adding dissolved pancrelipase products directly to formula prior to infusion was tried multiple times. Theoretically, the enzymes should act on the macronutrient substrates in the formula while contained in the formula bag. However, this method has not been studied in a clinical trial or published independent investigations. Furthermore, the practice contradicts manufacturer guidelines and goes against best practice recommendations that advise not to combine medication with enteral formula. [13] [14] [15] [16] [17] 24 In the second case, however, patient 2 could not take enzymes by mouth and was not a candidate for the alternative method of crushing or dissolving enzymes and adding them to formula. Prescribing the digestive cartridge was the next logical decision for both teams in need of a new therapy. Once early positive results were observed, therapy was continued.
The coordinated release of pancreatic enzymes and bicarbonate is essential for the digestion of all macronutrients but is most important for the digestion of fats. 25, 26 Lipolytic enzymes are only present in the stomach and pancreatic juices and are the least stable in the intestinal lumen. 26 In addition, undigested fats cause uncomfortable GI symptoms, such as steatorrhea, and result in the highest caloric losses. In contrast, enzymes that digest proteins and carbohydrates are present throughout the GI tract, with amylase in the mouth, pepsin in the stomach, and oligosaccharidases and peptidases present along the intestinal brush border. 25 To optimize absorption of macronutrients in the setting of EPI, both children were prescribed semi-elemental enteral formulas. The enzymatically hydrolyzed whey protein in the formula delivered peptides to the small bowel. Along the brush border of the small intestine, peptides can be absorbed by the enterocyte or be further broken down by exopeptidases and aminopeptidases prior to absorption. 27, 28 In addition, the formula contained a high proportion of medium-chain triglycerides, which do not require bile or pancreatic enzymes for digestion. 29 Unlike long-chain triglycerides, medium-chain triglycerides are passively absorbed through the portal system and are easily metabolized as an energy source. 29 Using the cartridge ensured digestion of the remaining long-chain triglycerides in the enteral formula. Even when pancreatic enzymes are delivered to the GI tract, either orally or through a feeding tube, their effectiveness depends on several factors. Gastric motility, bicarbonate release, intestinal pH, and dosing can all influence the performance of enzyme therapy. 18 If these factors are not synchronized physiologically, the pancrelipase can be ineffective. Trang and colleagues 18 reviewed the current literature concerning the use of PERT for pancreatic insufficiency. To meet FDA standards, the manufacturers tested the dissolution characteristics of enzyme microspheres in vitro. However, published data describing the dissolution of microspheres in vivo are not available. 18 Enzyme microsphere activity peaks at 30 minutes and diminishes over 2 hours. 21 In the CF population, patients are commonly advised to consider oral enzymes to be effective for 45 minutes after ingestion and instructed to dose them accordingly with meals and snacks. 1 Therefore, when dissolved enteric-coated pancrelipase product is delivered to the GI tract during a cycled or continuous feeding, the enzymes are likely not active the entire time, resulting in some malabsorption. As an alternative, the digestive cartridge provides continuous ex vivo digestion of fats throughout the entirety of the enteral feeding.
The first of the presented children, patient 1, had 15 cm of small bowel resected due to MI and volvulus. MI is a complication that occurs in approximately 10%-20% of CF newborns. If it cannot be effectively treated with hyperosmolar enemas, surgical intervention is required. 1, 30 Although there have been no negative long-term pulmonary outcomes associated with MI, neonates and infants with MI experience an increased clinical risk related to surgical intervention, gut perforation, peritonitis, and prolonged hospitalizations at birth. 31 The need for surgical intervention can then negatively affect stature and weight. Infants with MI are more likely to have an abnormal fatty acid profile and have higher caloric needs when compared with those with CF without MI. 32 At 4 months of age, patient 1 was failing to thrive and required GT placement. Despite aggressive intervention he remained in nutrition failure. He also struggled with ongoing severe GI symptoms, including frequent loose stools, GER, and emesis. His time-consuming pulmonary and enteral feeding treatments were a source of stress for his family, worsened by patient 1's food refusal. After the digestive cartridge was introduced, patient 1 experienced immediate increases in weight and height percentiles. His GI symptoms, including frequent emesis and loose stools, also significantly improved.
The second child, patient 2, was diagnosed with neuroblastoma at 16 months of age. Although the risk of cancer in patients with CF increases in adulthood, the incidence of malignancies in children with CF is low. 33 No association of neuroblastoma and CF has been reported. There have been only 3 cases of coexistent CF and neuroblastoma reported. One case was a 20-year follow-up of a young woman with CF and stage 3 neuroblastoma diagnosed at 22 months of age who underwent chemotherapy and surgery. 34 The other 2 cases were diagnosed at 3 months and 7 months of age. Both infants underwent successful surgical tumor resection. 35 Patient 2 also experienced initial weight gain and maintenance after starting enteral feeds with the digestive cartridge. Treatment for his neuroblastoma was aggressive during the early stages of therapy. Although it addressed the neuroblastoma, side effects of therapy caused physical setbacks, including limiting his overall nutrition intake. At that point, a relationship between his weight gain and the neuroblastoma treatment was unlikely. Using the digestive cartridge assisted with the tolerance of his enteral formula and ensured that he maintained adequate caloric intake. Patient 2's GI symptoms were difficult to assess in the setting of chemotherapy and the need for pain control with narcotics. He did not have obvious GI symptoms related to malabsorption.
In this tenuous case, if patient 2 had been unable to tolerate EN, PN would have been necessary. However, especially in the setting of immunosuppressive chemotherapy treatment, PN posed a greater risk for complications, such as bloodstream infections and PN-associated liver disease. Since initiation of the digestive cartridge, EN has been his most significant source of calories, and PN has been avoided. He has also demonstrated weight gain and growth despite being at increased risk for severe protein calorie malnutrition and growth failure during treatment for neuroblastoma.
In both cases, the new digestive cartridge was quickly accepted by the parents. Patient 1's parents observed several advantages to using the cartridge. His family had already tried 2 methods of dissolving enteric and nonenteric coated enzymes in solution prior to administration. This process required at least 30-45 minutes of preparation time with enteral feeding, yielding disappointing results. Introducing the cartridge saved time during his treatment regimen. Connecting the digestive cartridge in-line with the formula can be done when the tube feeding system is being set up and does not require extra time. Parents and providers were satisfied to see improved GI symptoms as well as linear growth and weight gain within a few months. In patient 2's case, at the time of GT insertion, he was refusing to take enzymes by mouth with food and formula. Due to an already overwhelming care regimen, the medical team did not want to further burden his parents with having to dissolve enzymes in solution. This task is challenging and would have been required multiple times per day. Initiating the digestive cartridge immediately after GT placement made his nutrition delivery easier and more effective.
Replacing a traditional therapy with a new technique often raises concerns related to economic costs for patients, hospitals, and society. This clinical observation was not designed to evaluate the economic impact of the new digestive cartridge. However, the cases could inform the design of formal economic evaluations, which have not been conducted. For example, one might compare the cost of the cartridge to the cost of oral pancreatic enzymes used with EN, including the cost of labor and supplies needed to prepare the mixture, whether it be in a home or hospital setting. Furthermore, these cases indicate the cartridge may improve nutrition outcomes, which may promote an overall healthcare cost savings by preventing or reversing malnutrition. However, this savings is difficult to quantify or directly link to the new therapy. Further research is needed to determine the effectiveness and economic impact of the digestive cartridge for people with fat malabsorption and EN.
Conclusion
The nutrition management for children with CF is complex. When accompanied by another severe diagnosis, optimizing growth of infants and toddlers poses an even greater challenge for parents and healthcare providers. Interventions are often maximized to prevent malnutrition and thereby minimize the risk of poor clinical outcomes. The cases presented in this report indicate that replacing PERT with the digestive cartridge for EN provided a significant therapeutic benefit to 2 children who were otherwise at high nutrition risk. Although the cartridge lacks protease and amylase enzymes, it has shown to be effective. Oral PERT is still required with meals and snacks containing fats and protein. With the use of the digestive cartridge, both toddlers thrived nutritionally, demonstrating weight gain, growth, and improved GI symptoms. This novel digestive cartridge is a promising therapeutic option for patients with fat malabsorption who require EN. More evidence is needed to observe its effect on long-term clinical outcomes and malnutrition.
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